Metastatic Breast Cancer — Optimizing the Use of Oral Selective Estrogen Receptor Degraders: Part 1

Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas review available efficacy and safety data guiding the optimal integration of oral SERDs into clinical practice. 

CME information and select publications here.